Naturium Salicylic Acid Serum 2%: the formula, label and bottle offer

The manufacturer names Salicylic Acid Serum 2% and describes an acne-focused serum. The posted US record names the same Naturium product, identifies e.l.f. Cosmetics as packager and shows an update dated November 14, 2025. That date belongs to the label entry; it is not the date of every bottle currently offered. Serum page and dated label.

Keeping the full name matters because a brand’s surrounding products cannot supply the missing details of this one. The product-version guide explains how to retain a product name and a source date without inventing a manufacturing or distribution history. Here, the name is a reliable starting point for the record, rather than a finding that an individual item has been verified.

Naturium publishes salicylic acid as the active and lists the accompanying ingredients. Water, propanediol, maltobionic acid, sodium polyacrylate and several other components appear in that panel. The posted label also supplies an inactive list. This is substantially more specific than a short set of featured ingredients, although it still describes a published formula rather than a tested sample. Manufacturer declaration and label ingredients.

FDA’s Drug Facts explanation separates inactive ingredients from the active, purpose and warnings. Those fields answer different questions about one product. Reading the inactive panel does not establish the quantities of each component, and the order or presence of a familiar name does not provide a recipe for reproducing the serum. FDA label fields.

The label states salicylic acid 2% and identifies acne treatment as the purpose. Its use statement addresses existing and future breakouts. These are product-specific label claims. They do not report the results of a trial conducted by this publication, and they do not establish performance against another finished preparation. Active, purpose and use.

FDA explains why an active ingredient and a use statement occupy separate fields. A concentration identifies one specification; the intended use tells readers which concern the record addresses. The matching-percentage discussion examines the remaining gap between those specifications and equal outcomes. There is no basis here for assigning the serum an effectiveness score from its percentage alone. Drug Facts explanation.

Naturium describes the formula as non-drying and uses dermatologist-tested wording. The returned page does not supply a full test report that would identify participants, comparison groups or the measures behind that description. The label separately warns about dryness and irritation when another topical acne product is involved. Both parts belong in the account. Brand descriptions and label warning.

AAD discusses dryness and irritation with salicylic-acid acne treatment more generally. That context does not prove this serum is uncomfortable, nor does it establish that a particular additional moisturizer solves a person’s concern. It explains why a reassuring adjective cannot become an individual comfort guarantee. AAD discussion.

The freshly checked manufacturer page displays $20 and identifies 1 fluid ounce, or 30 mL. The label’s package table also includes a 30 mL bottle record. Those observations let the price be reported with an identified size, while leaving the actual fulfilled item and final order charge untested. Current bottle display and package entry.

Net contents describe a container; they do not establish how long it would last for a particular person. FDA lists quantity separately from identity and strength. The plan-cost guide discusses why a commercial unit should retain its own meaning instead of becoming an invented monthly treatment expense. No checkout, shipping charge or future price was verified here. Package fields.

Naturium expressly says its online lists may differ slightly from packaging and distributor websites as formulas or regulatory information are updated. That caveat is useful information, not an inconvenience to remove from a review. It prevents the current panel from being treated as proof of every previously sold or currently supplied bottle. Ingredient-list qualification.

The older posted label date cannot settle that issue by itself. FDA also notes that product ingredients, warnings and labeling can change. Where an actual package is in question, the relevant record is that package and its version, rather than a merged list assembled from whichever page seems most complete. Label date and FDA version context.

The label includes an OTC monograph category and an NDC identifier. FDA describes the monograph pathway as conditional and cautions that NDC inclusion is not approval or verification of submitted information. These identifiers improve traceability without demonstrating this serum’s clinical advantage or certifying every applicable requirement. Naturium entry, monograph framework and NDC limits.

The practical question is whether the supplied bottle matches the published version and what finished-product evidence supports the claim of interest. The INKEY List review and COSRX review provide further product records to read separately. Neither link establishes a substitute or a winner, and this serum’s published detail remains distinct from testing it. Manufacturer record.